Provided by Tiger Trade Technology Pte. Ltd.

Acumen Pharmaceuticals, Inc.

3.16
-0.0300-0.94%
Post-market: 3.220.0632+2.00%19:30 EDT
Volume:716.03K
Turnover:2.32M
Market Cap:228.19M
PE:-1.93
High:3.34
Open:3.21
Low:3.14
Close:3.19
52wk High:3.60
52wk Low:1.21
Shares:72.21M
Float Shares:37.05M
Volume Ratio:1.45
T/O Rate:1.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6370
EPS(LYR):-2.0035
ROE:-120.50%
ROA:-45.77%
PB:3.98
PE(LYR):-1.58

Loading ...

Acumen Pharmaceuticals Inc - Expects to License Two Compounds From Jcr Pharmaceuticals in Q2 2026

THOMSON REUTERS
·
May 12

Acumen Pharmaceuticals, Inc. Q1 Basic EPS USD -0.33

THOMSON REUTERS
·
May 12

Press Release: Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

Dow Jones
·
May 12

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 11

Acumen Pharmaceuticals Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
May 08

Acumen Pharmaceuticals to join Bank of America Securities Health Care Conference fireside chat

Reuters
·
May 08

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

GlobeNewswire
·
May 06

Acumen Pharmaceuticals announces annual shareholder meeting via webcast

Reuters
·
Apr 24

BTIG Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS)

TIPRANKS
·
Apr 06

Acumen Pharmaceuticals’ Earnings Call: Promise Amid Pressure

TIPRANKS
·
Apr 05

Acumen files to sell 10.83M shares of common stock for holders

TIPRANKS
·
Mar 27

Acumen Pharmaceuticals Inc - Files for Offering of up to 10,833,331 Common Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Mar 27

Acumen Pharmaceuticals Price Target Maintained With a $8.00/Share by BTIG

Dow Jones
·
Mar 27

Acumen Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 26

Acumen Pharmaceuticals Q4 EPS $(0.41) Beats $(0.43) Estimate

Benzinga Earnings
·
Mar 26

Acumen Pharma posts smaller-than-expected 2025 loss on lower G&A costs

Reuters
·
Mar 26

Acumen Pharmaceuticals FY2025 EPS Loss Of $2.00 Vs. Loss Of $1.71 YoY, Cash, Cash Equivalents And Marketable Securities Of $116.9M With Cash Runway Into Early 2027

Benzinga Earnings
·
Mar 26

Acumen FY2025 net loss widens 18.57% to $121 million; operating loss climbs 8.62% to $124 million

Reuters
·
Mar 26

BRIEF-Acumen Pharmaceuticals, Inc. FY Income From Operations USD -123.832 Million Vs. IBES Estimate USD -127.9 Million

Reuters
·
Mar 26

Acumen Pharmaceuticals, Inc. FY Operating Expenses USD 123.832 Million

THOMSON REUTERS
·
Mar 26